This HTML5 document contains 59 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n10http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00793/identifier/wikipedia/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00793/identifier/pharmgkb/
n22http://bio2rdf.org/drugbank:
n16http://linked.opendata.cz/resource/drugbank/drug/DB00793/identifier/bindingdb/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00793/identifier/pubchem-compound/
admshttp://www.w3.org/ns/adms#
n12http://linked.opendata.cz/resource/drugbank/drug/DB00793/identifier/pubchem-substance/
n4http://www.drugs.com/mtm/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00793/identifier/kegg-drug/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00793/identifier/drugbank/
n9http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n20http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n5http://linked.opendata.cz/ontology/drugbank/
n6http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n17http://linked.opendata.cz/resource/drugbank/drug/DB00793/identifier/chemspider/
n19http://linked.opendata.cz/resource/atc/
n18http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00793
rdf:type
n5:Drug
n5:description
Haloprogin is used as a topical ointment or cream in the treatment of Tinea infections. Tinea infections are superficial fungal infections caused by three species of fungi collectively known as dermatophytes (Trichophyton, Microsporum and Epidermophyton). Commonly these infections are named for the body part affected, including tinea corporis (general skin), tinea cruris (groin), and tinea pedis (feet). Haloprogin is a halogenated phenolic ether administered topically for dermotaphytic infections. The mechanism of action is unknown, but it is thought to be via inhibition of oxygen uptake and disruption of yeast membrane structure and function. Haloprogin is no longer available in the United States and has been discontinued.
n5:generalReferences
# Harrison EF, Zwadyk P Jr, Bequette RJ, Hamlow EE, Tavormina PA, Zygmunt WA: Haloprogin: a topical antifungal agent. Appl Microbiol. 1970 May;19(5):746-50. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/5422306 # Harrison EF, Zygmunt WA: Haloprogin: mode of action studies in Candida albicans. Can J Microbiol. 1974 Sep;20(9):1241-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/4608935
n5:group
withdrawn approved
n5:indication
Used to treat fungal (Tinea) skin infections such as athlete's foot, jock itch, ringworm, and tinea versicolor.
n5:manufacturer
n10:271B63CE-363D-11E5-9242-09173F13E4C5
owl:sameAs
n9:DB00793 n22:DB00793
dcterms:title
Haloprogin
adms:identifier
n12:46504892 n13:3561 n14:DB00793 n15:D00339 n16:50194601 n17:3440 n21:Haloprogin n23:PA164768737
n5:mechanismOfAction
Haloprogin is a halogenated phenolic ether administered topically for dermotaphytic infections. The mechanism of action is unknown, but is thought to be via inhibition of oxygen uptake and disruption of yeast membrane structure and function. There is a higher incidence of cutaneous side effects with haloprogin, including irritation, burning, vesiculation (blisters), scaling, and itching. It is generally used when the infection is unresponsive to other antifungals.
n5:packager
n10:271B63CD-363D-11E5-9242-09173F13E4C5
n5:synonym
Haloproginum Haloprogin Haloprogina Haloprogine Halotex
n5:synthesisReference
U.S. Patent 3,322,813.
foaf:page
n4:haloprogin-topical.html
n5:IUPAC-Name
n6:271B63D4-363D-11E5-9242-09173F13E4C5
n5:InChI
n6:271B63DA-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n6:271B63D9-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n6:271B63D6-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n6:271B63D7-363D-11E5-9242-09173F13E4C5
n5:SMILES
n6:271B63D8-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n6:271B63D2-363D-11E5-9242-09173F13E4C5
n5:logP
n6:271B63D0-363D-11E5-9242-09173F13E4C5 n6:271B63D3-363D-11E5-9242-09173F13E4C5 n6:271B63EA-363D-11E5-9242-09173F13E4C5
n5:logS
n6:271B63D1-363D-11E5-9242-09173F13E4C5
n18:hasATCCode
n19:D01AE11
n5:H-Bond-Acceptor-Count
n6:271B63E0-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n6:271B63E1-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n6:271B63DB-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n6:271B63DC-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n6:271B63DE-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n6:271B63DD-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n6:271B63DF-363D-11E5-9242-09173F13E4C5
n5:affectedOrganism
Dermatophytic fungi including Trichophyton, Microsporum and Epidermophyton
n5:casRegistryNumber
777-11-7
n5:category
n5:containedIn
n20:271B63CF-363D-11E5-9242-09173F13E4C5
n5:Bioavailability
n6:271B63E5-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n6:271B63E7-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n6:271B63E8-363D-11E5-9242-09173F13E4C5
n5:Melting-Point
n6:271B63E9-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n6:271B63E4-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n6:271B63E3-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n6:271B63E6-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n6:271B63D5-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n6:271B63E2-363D-11E5-9242-09173F13E4C5